Researchers have recently developed the drug zotatifin, a new cancer medication. But unlike many common cancer therapies that focus on stopping cell growth signals or targeting genes in the DNA, zotatifin instead disrupts the cellular machinery responsible for building proteins (which is what genes code for).
Why is this important? All cells, including cancerous ones, need proteins to carry out essential functions, such as cell growth and division. In particular, a molecule called eIF4A is involved in increasing cellular protein production, which allows cancer cells to function.
Zotatifin could potentially treat many different types of cancers.
Image Source: KARRASTOCK
Zotatifin can inhibit (prevent the effects of) eIF4A. Once eIF4A is blocked, cancer cells cannot produce some of the proteins required for their survival. This could slow down cancer cell growth or even trigger cell death. And even better, this would spare normal, noncancerous cells, because they don’t depend as much on elF4A.
Zotatifin is particularly exciting for researchers because of its ability to target processes that occur in a wide variety of different cancers, which means it could potentially be an effective medication for many cancerous conditions. Right now, the drug is in clinical trials assessing its potential as a treatment for breast cancer. Early results have been encouraging, with some patients experiencing reduced tumor growth.
There is potential for zotatifin to be used for treating other types of cancer as well, such as prostate cancer. One of the key players in prostate cancer is the androgen receptor, and zotatifin has been found to block cells from producing them, making it a viable option for patients whose cancers have stopped responding to hormone treatments.
As research on zotatifin is still in its infancy, it’s still unclear which cancers zotatifin will be most effective in treating. However, these promising preliminary results for breast and prostate cancer indicate that zotatifin might one day become a prominent and common cancer treatment option, especially for people whose cancers have become resistant to existing therapies.
Featured Image Source: Catalin
